Sign in
Active, not recruitingPhase 3

Multicenter, randomized, double-blind, Phase III study of intravenous TAD® 600 mg/4 ml solution for injection to evaluate efficacy and safety in preventing myocardial injury in patients with pneumonia

Key facts

Who runs it
Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.
Where
Italy7 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
178 people, planned
Started
7 May 2024
Ended
1 Nov 2024
Type of study
Interventional
Record updated
25 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients with an age of ≥ 18 and ≤ 85 years
  • Diagnosis of CAP or HAP requiring hospitalization
  • Patients with one of the following (a or b*): a. At least one cardiovascular comorbidity: • Chronic atrial fibrillation • History of ischemic heart disease (≥ 3 months) • History of heart failure (NYHA class I e II) • Cardiac Valvular Disease • Previous (≥ 2 months) episode of myocarditis or pericarditis b. Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score ≥ 7.5% for patients 40-50 years old, score ≥ 10% for patients 50-69 years old, and score ≥ 15% for patients ≥ 70 years old). * Please note that if the patient meets inclusion criterion 3(a), the CVD risk should not be calculated
  • Provision of written informed consent as approved by the Ethics Committee (EC) by the patient or his/her legal representative

Who cannot take part

  • Use of drugs containing sacubitril
  • Use of drugs with antioxidant activity in the last 3 months
  • Participation in other investigational drug or device clinical trials within 30 days prior to study screening
  • History of hypersensitivity to glutathione or any excipients
  • Recent (< 1 month) myocardial revascularization
  • History of severe heart failure (NYHA class III and IV)
  • History of severe liver disease
  • Severe to end-stage renal failure (eGFR < 30 mL/min)
  • Active malignancy with a life expectancy < 2 years
  • Routine use or abuse of narcotics
  • Use of invasive mechanical ventilation
  • Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol
  • Women of child-bearing potential not using at least one effective contraceptive method for the entire trial
  • Pregnant or breastfeeding women
  • Women of child-bearing potential not using at least one effective contraceptive method for the entire trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

TAD® used as an add-on treatment, due to the presence of the sodium salt glutathione, could be effective and safe in preventing myocardial injury in hospitalized patients with pneumonia.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
25 June 2025